Enrolling Metabolic Dysfunction-associated Steatohepatitis Drug: Placebo Drug: ECC4703 A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants wi
K.D'AlessioD
It is available in six doses ranging from 0.8 mg to 17.2 mg, designed to be started at the lowest dose and gradually increased over time to reduce side effects
Daily oral dosing, particularly FOUNDAYOs restriction-free take it anytime convenience, may prove to have significantly better long-term adherence profiles than weekly injections, which require patients to self-inject, rotate injection sites, and manage sharps disposal
-: GHK-Cu
All of this information allows us to determine if medication is suitable for you, so we can develop a personalized treatment plan to help you achieve and maintain healthy weight loss